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Impairment of maturation of BMP-6 (35
kDa) correlates with delayed fracture
healing in experimental diabetes
Qidong Guo1, Weijie Wang2, Rami Abboud2 and Zheng Guo3*
Abstract
Background: Although it is known that diabetes interferes with fracture healing, the mechanisms remain poorly
understood. The aim of this study was to investigate the correlation of BMP-6 and BMP-9 with the impairment in
fracture healing in diabetes, by analyses of the difference in size and calcification of the callus, mechanical
endurance, and expressing BMP-6 and BMP-9 in the callus, using a clinical related diabetic rodent model.
Methods: We evaluated femur fracture healing by quantification of size and calcification of the callus by X-ray,
histological and histochemical images, loading capacity of the fractured bone, and amount of BMP-6 in the callus
and the bones using Western blot assay.
Results: Significant upregulation of BMP-6 in the callus and the fractured bones of both non-diabetic and the
diabetic animals was observed, at the end of the second and the fourth weeks after fracture. However, significantly
lower levels of BMP-6 at 35 kDa with smaller sizes of calcified callus and poor loading capacity of the healing bones
were detected in the diabetic animals, compared to the non-diabetic controls. The impairment of the maturation
procedure of BMP-6 (35 kDa) from precursors may be underlying the downregulation of the BMP-6 in diabetic
animals.
Conclusions: It could be concluded that the delayed fracture healing in the diabetic animals is correlated with
deficiency of BMP-6 (35 kDa), which may be caused by impairment of maturation procedure of BMP-6 from
precursors to functioning format. This is a primary study but an important step to explore the molecular
pathogenesis of impairment of fracture healing in diabetes and to molecular therapeutic approach for the
impairment of fracture healing.
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Background
Diabetes is a major challenger for human health. More
than 400 million people are living with the disease and it
is estimated that the number will rise to 700 million by
2045 [1]. Cumulating evidence indicates that diabetes
impairs bone health and fracture healing [2]. Among the
diabetes-related comorbidity, low energy trauma fracture
is one of the major causes of morbidity and mortality of
diabetic patients, due to the increased fracture risk and
the impaired healing procedure, in comparison with
non-diabetic cohort [3]. Clinical studies indicate a sig-
nificantly higher incidence of delayed union and non-
union after fracture in diabetic patients, compared to the
nondiabetic ones [4, 5]. The fracture nonunion, rating at
5–10% [6], is still a major complication causing longer
physical disability, pain, mental dysfunction, and
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expenditure on the treatment world widely. The mech-
anism underlying the nonunion was thought to be
mainly associated with severity of injury in the fracture
site and the mode of surgical treatment [7, 8]. However,
progression to nonunion is not fully explained by these
factors alone [5]. Although a considerable effort has
been made to identify the impact of diabetes on osteo-
blasts and bone formation [9–11], there have been few
studies that investigate the molecular mechanism by
which diabetes affects the process of fracture healing
[12, 13]. Therefore, exploring the molecular, pathogen-
etic changes in the healing bone in diabetes is important
for further understanding of the pathology of impair-
ment of the fracture union.
Bone morphogenetic proteins (BMPs), as a member of
the transforming growth factor-β (TGF-β) superfamily,
mediate multiple biological processes including regulation
of bone formation [14]. BMP-2 has been locally applied to
achieve bone regeneration in diabetes [15]. However, the
effect of other BMPs-6 and BMP-9 on fracture healing in
diabetes has not been reported. In this study, we investi-
gated the difference in expressions of BMP-6 and BMP-9
in the healing femurs between diabetic and non-diabetic
animal models, while the change in radiological, histo-
logical, and mechanical parameter was evaluated, making
an attempt to reveal molecular pathological impact of
BMP-6 and BMP-9 on the fracture healing.
Method and material
The study was conformed to the Guide for the Care and
Use of Laboratory animals (Copyright 2011 by the Na-
tional Academy of Sciences) and approved by the Acad-
emy and Ethics Committee of University of Dundee.
Experimental protocol
Healthy male Sprague-Dawley rats weighing 255 ± 7 g
were randomly assigned to diabetic group (n = 22) and
age-matched non-diabetic control group (n = 22), ac-
cording to previous study [13] and statistical power ana-
lysis. Diabetes was induced by intraperitoneal injection
of streptozotocin (STZ). Femur fracture was induced 2
weeks after induction of diabetes. The difference in the
healing of femur fracture between diabetic and non-
diabetic rats was evaluated by X-ray examination at the
end of the second, the fourth, and the eighth weeks after
induction of the fracture. The mechanical test was per-
formed at the end of the second and the fourth weeks
after fracture. The expressions of BMP-6 and BMP-9 in
the healing callus and the bones were quantitatively ana-
lyzed in both of diabetic and non-diabetic animals.
Diabetes model
The animals assigned to diabetic group were treated
with intraperitoneal injection of STZ (50 mg/kg,
dissolved in 0.1 mol/L citrate buffer at pH 4.5) after 16-
h fasting. Drinking water was supplied immediately after
the treatment, while food was supplied 3 h after the in-
jection of STZ. Diabetes was defined by a sustained
blood glucose concentration greater than 16.7 mmol/L
[16] 24 h after the injection of STZ, while those that
showed blood glucose less than 16.7 mmol/L were ex-
cluded from further experiment. Body weight, food, and
water consumption of the animals were closely moni-
tored. Glucoses in the blood and urine were tested on
the first post-injection day and then once every 3 days
(Fig. 1).
Fracture model
At the end of the second week after the induction of dia-
betes, transverse femoral fracture was induced. The ani-
mals were scheduled on 16-h fasting before fracture.
The anesthesia of the animal was induced by inhalation
of 5% of sevoflurane (delivered in 100% of oxygen) and
maintained with 3.5~5% of sevoflurane, while spontan-
eous respiration of the animal was maintained. Gentami-
cin (8000 IU, 0.2 mL) was used (injected
subcutaneously) to prevent infection. Left sciatic nerve
was blocked with bupivacaine (0.125%, 1 mL). The left
thigh of the animal was cleaned, shaved, and sterilized
with iodophor. A 10 mm incision was made medial to
the ligamentum patellae and then the tendon was
bluntly dissected with mosquito-type hemostatic forceps.
The ligamentum patella was drawn laterally with double
1-0 suture to expose the joint capsule. Then the capsule
was opened with mosquito-type hemostatic forceps to
expose the patellofemoral groove. A K-Wire (40 mm)
was drilled into the marrow cavity in a retrograde fash-
ion from the groove, as an internal fixation. The drilling
was stopped when met resistance, which meant the dis-
tal end of the pin had been drilled into proximal cortex
of the femur. The incision was closed with 4-0 suture.
Then the fixed thigh was placed in abduction and exter-
nally rotated position on the guillotine system, with
great trochanter on one supporter and supracondyle on
the other. The impact distance of the blade was set at
one-half of the long diameter of the contralateral femur.
Then a 500-g weight fell freely from 300 mm height to
drive the blade down, a mid-diaphyseal fracture was in-
duced. The animal was allowed to recover from the
anesthesia and the surgery. The data were not included
in this report for the animals that died at any time be-
fore the end of the experiment observation.
Radiology
Seven animals in each of the diabetic and the non-
diabetic groups were scheduled for X-ray examination,
at the end of the second and the eighth weeks following
fracture, while eight animals in each of the diabetic and
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non-diabetic groups received radiological evaluation, at
the end of the fourth week. X-ray examinations (Philips®
Medical system, Nederland) were carried out for the ani-
mals under anesthesia (with 25% urethane, 1.25 g/kg,
i.p.), in a supine position with the fractured thigh in ab-
duction and externally rotated position, at the end of the
second, the fourth, and the eighth post-fracture weeks.
The size and calcification ratio of callus were evaluated
and analyzed with ImageJ® software (National Institutes
of Health, USA).
Mechanical test
The fractured femurs were collected from nine animals
(non-diabetic, n = 5 and diabetic, n = 4), at the end of
the second week after surgery and from 11 animals
(non-diabetic, n = 5 and diabetic, n = 6) 4 weeks follow-
ing fracture, after euthanasia of the animals. A three-
point bending system was employed to evaluate the
pressure taken to break the healing callus.
Histological and immunohistochemistry assay
Two fractured femurs were collected after euthanasia of
the animals from each experimental group. The samples
were then fixed in 4% of paraformaldehyde solution for
72 h. The distal and proximal ends of the femurs were
cut off then the mid-shaft calluses were decalcified in
10% ethylene diamine tetraacetic acid (EDTA) solution
at a temperature of 40 °C for 1 week. Then the calluses
were cut into 5-μm-thick sections using a cryostat (Leica
CM 1850, Germany). The sections were assigned for
hematoxylin-eosin (HE) stain and immunohistochemis-
try (IHC) assay.
For immunohistochemistry assay, the sections were
processed with primary anti-BMP-6 and anti-BMP-9
(Santa Cruz Biotechnology Inc., California, USA) and
the secondary antibodies (Zhongshan Biotechnology
Inc., Beijing, China) according to the instructions of the
suppliers. Chromagen 3,30-diaminobenzidine
(Zhongshan Biotechnology Inc., Beijing, China), brown
reaction product, was added as the final substrate to
visualization of the antigens.
Western blot
The fractured and the intact (the contralateral) femurs
were collected from ten animals of non-diabetic (n = 5)
and diabetic groups (n = 5), 2 weeks after surgery and
from other 12 animals of non-diabetic (n = 6) and dia-
betic groups (n = 6), 4 weeks after induction of fracture.
The mid-shaft callus and bones (in fractured femurs) or
the bones in the corresponding position (in the intact fe-
murs) were resected and grinded in liquid nitrogen (−
196.56 °C). Then the total protein was extracted from
the callus for Western blot assay, as we previously re-
ported [17]. The ECL chemical luminescence method
was employed to detect the labeled antigen. The values
of optical density of all blotting bands were measured
with Quantity One® software (Bio Rad, USA). The values
of BMP-6 and BMP-9 were standardized by being di-
vided by the values of GAPDH. Then the standardized
values were analyzed.
Fig. 1 The diabetic model building. Rats showed typical diabetic symptoms including high fasting blood glucose (a), urine glucose (b),
polyphagia, polydipsia (c), loss of body weight (d), and lower growth rate (e)
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Statistical analysis
The sample size of the experiments was determined
using G*Power software (version 3.1.9.7). According
to the primary observations in the pilot experiments,
the standardized effect size was calculated based on
the differences between the means of the experimen-
tal groups and the standard deviations. The significant
level, ‘α err prob’ at 0.05 was chosen. Data of the re-
sults are presented as mean ± standard deviation
(S.D.) and compared between two groups using the
Student’s t test, or by one-way analysis of variance
(ANOVA), using Tukeys’ multiple comparison test for




Data reported here were collected from the 22 animals
that presented significant high level of glucose in blood
and in urine (Fig. 1a, b, p < 0.01) and lived through the
observation period. The consumption of food and
drinking water was significantly increased while the body
weight and growth rate were significantly reduced in the
diabetic animals, compared with the non-diabetic con-
trols (Fig. 1c–e, all p < 0.01).
Radiological evaluation
The results showed that, at the second and the fourth
weeks after fracture, the calluses of the fractured femurs
in the diabetic animals were much weaker than their
non-diabetic counterparts, by presenting predominant fi-
brous calluses with few calcified calluses (Fig. 2). At the
eighth post-fracture week, the non-diabetic group had
almost finished fracture remodeling while diabetic one
had not (Fig. 2). Thus, the results of radiological exams
at the end of the fourth week were employed in com-
parative and quantitative analyses. The size of callus was
presented as the ratio of the callus diameter to the fem-
oral diameter. Based on the analysis, the significantly
smaller size of calluses was observed in diabetic animals,
compared to that of the non-diabetic group (non-dia-
betic vs diabetic, 2.14 ± 0.18 vs. 1.64 ± 0.14, n = 8, p <
0.05). The calcification ratio of diabetic calluses was also
significantly lower than that of non-diabetic calluses
(non-diabetic vs. diabetic, 60.61 ± 2.13% vs. 53.40 ±
6.49%, n = 8, p < 0.05).
Mechanical evaluation
The mechanical endurance of diabetic callus was mark-
edly reduced than that of non-diabetic callus at both the
second and the fourth post-fracture weeks. But only the
difference was found statistically significant, between the
non-diabetic and diabetic groups at the end of the fourth
week of fracture (non-diabetic vs. diabetic: 217.49 ±
39.63 kPa vs. 161.85 ± 38.33 kPa, p < 0.05, Table 1).
Fig. 2 Radiological evaluations of the healing. Smaller calluses with few calcified calluses were observed in diabetic animals, compared with that
in normal controls. At the eighth post-fracture week, the non-diabetic group had almost finished fracture remodeling while diabetic one had not
Table 1 Mechanical endurance of the fractured bones (kPa)
Groups 2nd week 4th week
Non-DM (n = 5) DM (n = 4) Non-DM (n = 5) DM (n = 6)
92.40 30.19 170.88 211.92
110.50 28.72 260.58 212.80
12.90 48.66 230.39 108.45
61.55 87.93 255.30 148.61
130.73 170.30 151.60
137.73
Mean 81.62 48.88 217.49 161.85*
SD 41.20 23.88 39.63 38.33
*p < 0.05, compared with the ‘non-DM’ at the end of fourth week
after fracture
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Histological and immunohistochemistry assay
It can be clearly seen that the fracture ends were sur-
rounded by a spindle red-stained callus. Calcification
started from the four angles formed by periosteum and
cortex (Fig. 3a). The (red-stained) callus was significantly
smaller in the diabetic group at the second and the
fourth post-fracture weeks (Fig. 3b and c vs. e and f). At
the eighth week after the fracture, the fracture in the
non-diabetic control was well healed and showed typical
double-track sign as intact bones (Fig. 3d). However, the
cortex of the fracture bones in diabetic animals was still
under remodeling (Fig. 3g), which was consistent with
the results of radiological evaluation (Fig. 2).
The immunohistochemistry assay revealed that BMP-6
and BMP-9 were expressed in skeleton muscles, perios-
teum, marrow, and woven bone inside the callus. The
immunoreactive positive spots were also found scattered
in osteocytes and extracellular matrix in cortex (Fig. 4a,
b showing expression of BMP-6). Fewer BMP-6 immu-
noreactive materials were detected in the cortex of the
bones of the diabetic animals (Fig. 4f, g, and h), com-
pared with the non-diabetic ones (Fig. 4c–e).
Fig. 3 HE stained healing calluses. Fracture end surrounded by a spindle red-stained callus with calcification started from the four angles formed
by periosteum and cortex (a). Smaller size of calluses was found in diabetic animals at the end of the second and fourth week after fracture (e, f)
than that of the normal group (b, c). At the end of the eighth week, calluses from the normal group had finished reconstruction (d) while
calluses from the diabetic group had not (g)
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Fig. 4 IHC of healing bone. BMP-6 in skeleton muscles (labeled as ‘m’), periosteum (as ‘p’), marrow and woven bone (as ‘w’) inside the callus.
Positive spots were also found scattered in osteocytes (as ‘oc’) and extracellular matrix in cortex (as ‘c’). Fewer BMP-6 immunoreactive materials
were detected in the cortex of the bone of the diabetic animals (f, g, h), compared with the non-diabetic ones (c, d, e)
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Changes of BMP-6 and BMP-9
The results of Western blot assay showed multiple
bands of immunoreactive positive to BMP-6. Four of
them located between 49 and 90 kDa. One was be-
tween 35 and 49 kDa and another band was aligned
with the marker of 35 kDa (Fig. 5a, d). The optical
density values of all bands of different molecular
weights were quantified and analyzed. Although the
pattern of band layout was not strictly identical
among each lane (sample), four most-frequently pre-
sented bands, including the three located between 90
and 45 kDa and the one with a molecular weight of
35 kDa, were compared and analyzed. As the exact
molecular weight of the other three bands was un-
known (not aligning with any of the molecular
marker), here they were presented as BMP-6-1, -2,
and -3 (in the order of molecular weights from high
to low, as shown in Fig. 6a–f). Only the 35 kDa one
was stably upregulated in fractured femurs at both
the second and the fourth post-fracture weeks (Figs.
5a, c, d, f and 6g, h). However, only one band of im-
munoreactive to BMP-9 was found, but no relation-
ship to fracture was detected (Figs. 5b, c, e, f and 7).
Fracture and BMP-6
In comparison with the intact femurs, the expression of
the BMP-6 (35 kDa) was significantly upregulated in
fractured femurs of both the diabetic (Figs. 5a, c, d, f and
6g, h) and the non-diabetic rats (Fig. 6a–h). For the
time-dependent expression differences, greater amount
of expression of BMP-6 (35 kDa) was found at the end
of the second week after fracture in both of the fractured
and the non-fractured femurs of the diabetic (n = 5) and
the non-diabetic animals (n = 5), when compared to
those at the end of the fourth post-fracture week (dia-
betic group, n = 6; non-diabetic group, n = 6; Figs. 6g, h
and 7, all p < 0.05). The findings indicate the participa-
tion of BMP-6 (35 kDa) in the healing of the fracture
from the early time after fracture.
Diabetes and BMP-6
However, the values of the BMP-6 (35 kDa) in both of
the fractured and the non-fractured femurs from dia-
betic rats were much lower than their non-diabetic
counterparts. Precisely, compared with the non-diabetic
rats, the BMP-6 (35 kDa) in fractured and non-fractured
femurs of the diabetic ones reduced by 25.95% (n = 5)
Fig. 5 Western blot assay. Among the multiple bands of immunoreactive positive for BMP-6 (a, d), only the 35 kDa one was stably upregulated in
fractured femurs at both the second and fourth post-fracture week; the only one band for BMP-9 was found, but not related to fracture (b, e)
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and 19.15% (n = 5) respectively, at the end of the second
post-fracture week, but by 34.01% (n = 6) and 18.83% (n
= 6) respectively, at the end of the fourth week (all p <
0.05, Figs. 6g, h and 7). Therefore, it may indicate that
the BMP-6 (35 kDa) participated in fracture healing,
which was significantly inhibited by diabetes (by up to
34.01%).
Ratio of BMP-6 molecules of different molecular weights
The ratio of the immunoreactive BMP-6 in forms of dif-
ferent molecular weights to the BMP-6 in 35 kDa was
Fig. 6 Quantification of 35 kDa BMP-6. 35 kDa BMP-6 was found upregulated in fractured femurs compared with intact femurs in both diabetic
and non-diabetic animals (g and h, all p < 0.05). While in diabetic animals, 35 kDa BMP-6 was found significantly down-regulated, compared with
non-diabetic ones in both fractured and intact femurs (all p < 0.05). NF normal fractured, NI normal intact, DF diabetic fractured, DI diabetic intact;
*p < 0.05, compared with normal fractured; #p < 0.05, compared with diabetic fractured
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analyzed from the data collected from the animals of
diabetic and non-diabetic group, at the end of the fourth
week after femur fracture, to figure out the mechanism
underlying the downregulation of the BMP-6 (35 kDa).
The results showed significantly higher ratios in the
BMP-6-1/BMP-6 (35 kDa) in diabetic ones (normal frac-
ture vs. diabetic fracture, 1.19 ± 0.44 vs. 4.89 ± 1.69, n =
6, p < 0.01) and BMP-6-3/BMP-6 (35 kDa) (normal frac-
ture vs. diabetic fracture, 0.47 ± 012 vs. 1.47 ± 0.43, n =
6, p < 0.01). The results indicate the impairment of the
maturation of BMP-6 (35 kDa) in fractured bones of dia-
betic animals (Table 2).
Discussions
It was not the first time that the connection between
diabetes and fracture was studied. Skeleton and endo-
crine are not two isolated systems. Although the main
function of bones is to support body weight, to provide
attachments for muscles during movement, and to form
cavities which protect organs, recent studies revealed
that bone plays important roles in glucose and fat
homeostasis and interacts with energy metabolism as an
endocrine organ. For instance, osteocalcin, an osteoblast
secreted protein, plays important roles in regulating
bone metabolism and systemic glucose metabolism [18–
21].
On the other hand, diabetes also has dramatic influ-
ence on bone formation and fracture healing. Terada
and colleagues found that high glucose concentration
impaired the proliferative response of osteoblasts to in-
sulin-like growth factor-1 (IGF-1) and delayed osteoblast
differentiation [22]. Sustained hyperglycemia, which is
commonly seen in diabetic patients, increases formation
of advanced glycation end product (AGE) which has been
shown causing dose-dependent reduction of bone forma-
tion via the receptor of AGE [23]. The findings suggest
that both hyperglycemia itself and its end products have
negative effects on bone formation and fracture healing.
Fracture healing and BMP-6
Although the potential participation of BMP-6 in bone
formation was indicated in previous researches [18, 24–
26], the role of the compound in diabetes-related im-
pairment of fracture healing has not been elucidated.
The novel finding of this study indicates that a particular
member of the BMP-6 family, with a molecular weight
of 35 kDa, may play an important role in fracture heal-
ing. The significantly higher (by 30–40 times) BMP-6
(35 kDa), detected at the end of the second post-fracture
Fig. 7 The impact of fracture and diabetes on BMP-6 and BMP-9. BMP-6 (35 kDa) was significantly upregulated in fractured femurs of both the
normal and diabetic animals. Significantly lower level of BMP-6 (35 kDa) was observed in the fractured and intact femurs of the diabetic animals.
No significant change in BMP-9 was detected among the fractured, intact, diabetic and non-diabetic animals
Table 2 Ratio of optical density of the BMP-6 bands (M ± SD)
Groups BMP6-1/35 kDa BMP6-2/35 kDa BMP6-3/35 kDa
Normal fracture 1.19 ± 0.44 0.55 ± 0.41 0.47 ± 0.12
Normal intact 3.85 ± 2.02& 2.77 ± 1.84& 3.50 ± 2.59&
Diabetic fracture 4.89 ± 1.69* 0.59 ± 0.25 1.47 ± 0.43*
Diabetic intact 5.17 ± 1.78 1.08 ± 0.51 4.61 ± 2.28#
&p < 0.01, compared with ‘Normal fracture’; *p < 0.01, compared with ‘normal
fracture’; #p < 0.05, compared with ‘Diabetic fracture’
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week, compared with that the fourth week, may indicate
that the BMP-6 plays active roles in the early stage of
fracture healing, i.e., chondrogenesis and early osteogen-
esis. Moreover, the early upregulation of the BMP-6 (35
kDa) may be derived by the post-translational mechan-
ism, because neither difference in the transcription cop-
ies of the mRNA coding BMP-6 nor the BMP-6 proteins
with higher molecular weights than 35 kDa was detected
in previous studies [18, 24, 25].
Diabetes and BMP-6
As the molecular weights of the other proteins showing
immunoreactive positivity to the BMP-6 antibody were
greater than the 35 kDa, if the BMP-6 at 35 kDa was the
functioning form, the others (with greater molecular
weights) could be the precursor and mid-products.
Therefore, as the BMP-6 at 35 kDa was significantly up-
regulated in the fractured femurs, the volume of precur-
sor and mid-products may be getting lower because of
the shift of the precursor and the mid-products to the
smaller functioning BMP-6 (35 kDa).
Our finding indicates that the transforming procedure
from the molecules of greater molecular weights to the
BMP-6 at 35 kDa was inhibited in diabetic animals.
Therefore, the finding may suggests that diabetes down-
regulates the BMP-6 at 35 kDa through slowing down
its maturing procedure. Obviously, the underlying mech-
anism is worth to be investigated.
Although the results in this study indicating BMP-6
(35 kDa) may play an important role in promotion of re-
generation of bone and fracture healing, the findings re-
ported here are primary, especially considering the
limited sample sizes in this study, because of the ethic
and economic consideration. Further investigation needs
to be carried out targeting the mechanism underlying
the pathogenesis of the delayed maturation of BMP-6
(35 kDa) and fracture healing, and the therapeutic ap-
proach via reversion of the pathological downregulation
of BMP-6 (35 kDa).
In conclusion, downregulation of BMP-6 at 35 kDa
may correlate with the impaired fracture healing in dia-
betes. The finding may suggests a potential target for the
intervention of the pathological mechanism underlying
the impairment of fracture healing in diabetes.
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